Back

Beta-blocker therapy and all-cause mortality after percutaneous coronary intervention: a state-wide propensity score matched analysis stratified by left ventricular ejection fraction

31 August 2026 (08:39 - 08:51)
Organised by: Logo
Congress Presentation Part of: Secondary prevention strategies in coronary artery disease Secondary Prevention ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mrs Pilar Ignacia Cataldo Miranda

Monash University, Melbourne (Australia)

4 More presentations in this session

Presentation thumbnail
Time-to-benefit of glucagon-like peptide-1 receptor agonists for cardiovascular protection in type 2 diabetes
Miss C. Chang (New Taipei, TW)
Abstract Slides Video
Presentation thumbnail
SELECT in the light of FAST-MI. Potential population-based benefit of semaglutide 2.4mg/week on mortality, an extrapolation from the SELECT trial results to the FAST-MI registries.
Professor F. Schiele (Besancon, FR)
Abstract Slides Video
Presentation thumbnail
Distinct phenotype of very early-onset coronary artery disease (≤35 years): baseline findings from a multicentre prospective cohort
Miss X. Ding (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Beyond the genome: the dominant role of biological age over polygenic risk in post-PCI mortality prediction.
Miss M. Liu (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention strategies in coronary artery disease
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 08:39 CET
You may be interested in
thumbnail
Congress Session
HOT LINE 3
30 August 2025
thumbnail
Congress Presentation
Comparative clinical outcomes of nebivolol versus bisoprolol in patients with STEMI after primary PCI: a propensity-score matched analysis
29 August 2026
thumbnail
Congress Presentation
Heart failure clinic follow-up and outcomes after hospitalisation: a propensity-weighted cohort study
31 August 2026
thumbnail
Congress Presentation
Clinical outcomes of carvedilol versus metoprolol in patients with heart failure with preserved ejection fraction following myocardial infarction
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources